Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
KTTAW
KTTAW
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KTTAW News
Pasithea Therapeutics Reports Encouraging Pharmacokinetic Data for PAS-004 Tablet in Ongoing Phase 1/1b Trial Involving Adult NF1 Patients
Nov 21 2025
Newsfilter
Pasithea Therapeutics Launches Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Study of PAS-004 in Adult Patients with NF1
Nov 04 2025
Newsfilter
Pasithea Therapeutics Begins Enrollment of Cohort 2 After Favorable SRC Review for Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Sep 08 2025
Newsfilter
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Jul 31 2025
Newsfilter
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
Jun 11 2025
Newsfilter
Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
May 20 2025
Newsfilter
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
May 14 2025
Newsfilter
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
May 07 2025
Newsfilter
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering
May 06 2025
Newsfilter
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004
May 06 2025
Newsfilter
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients
Apr 29 2025
Newsfilter
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Apr 10 2025
Newsfilter
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
Jan 14 2025
Newsfilter
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Nov 20 2024
Newsfilter
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Sep 26 2024
Newsfilter
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
Sep 09 2024
Newsfilter
Show More News
